Promoter-targeted anti-nociceptive HSV-1 vectors have differential effects on pain based on the neuronal population targeted by Doyal, Mark F.
 Promoter-targeted anti-nociceptive HSV-1 vectors have differential effects on pain based 
on the neuronal population targeted 
 
 
 
 
 
 
 
 
by 
Mark Frederick Doyal 
Bachelor of Arts in Biology, University of Virginia, 2006 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Medicine in partial fulfillment  
of the requirements for the degree of 
Master of Science 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2015 
 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
Mark F. Doyal 
 
 
 
It was approved by 
Saleem A. Khan, PhD. Professor, Department of Microbiology and Molecular Genetics 
Ronald C. Montelaro, PhD. Professor, Department of Microbiology and Molecular Genetics 
 Joseph C. Glorioso III, PhD. Professor, Department of Microbiology and Molecular Genetics 
 
 
 ii 
Copyright © by Mark F. Doyal 
2015 
 iii 
 Herpes simplex virus-1 (HSV-1) is a neurotropic virus capable of infecting sensory neurons 
through their termini at any site on the body. Upon infection, the HSV-1 genome persists in 
nuclei within sensory ganglia for the life of the host. Replication-defective HSV-1 vectors allow 
for the efficient transduction of diverse populations of sensory neurons without risk of herpetic 
disease and therefore represent an ideal gene therapy vehicle for the treatment of peripheral 
neurological diseases, including chronic pain. To evaluate the potential of HSV-1 vectors to treat 
pain, a set of replication-defective HSV-1 vectors was generated, driving the expression of an 
anti-nociceptive product (GlyRIS) from neuronal promoters to target expression to distinct 
neuronal populations. Specifically, the TRPV1 promoter was used to target heat-sensitive 
nociceptors, and the NF200 promoter was used to target large diameter Aβ-fibers which may be 
recruited for pain signaling after injury or inflammation. The ubiquitously expressed CMV 
promoter was used as a control. As expected, when these vectors were used to transduce cultured 
DRG cells, the neuronal promoters largely expressed in neuronal cells only, while the CMV 
promoter expressed in neuronal and support cells. For pain studies, vectors were injected under 
the skin of the right hind footpad in rats. After nine days, baseline thermal and mechanical 
withdrawal thresholds were taken before and after the application of the ligand ivermectin, 
activating vector-delivered GlyRIS. TRPV1-GlyRIS transduced rats and to a lesser extent CMV-
GlyRIS transduced rats showed increased thermal withdrawal thresholds on the transduced side 
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after ligand administration. Resiniferatoxin (RTX) was then injected to ablate TRPV1+ neurons 
and induce mechanical allodynia. After 20 days, all RTX-injected rats showed increased thermal 
withdrawal thresholds with a loss of dependence on vector injection and ligand administration, 
consistent with TRPV1+ neuron ablation. All RTX-injected rats developed bilateral mechanical 
allodynia, except for the NF200-GlyRIS transduced rats (Aβ-targeted) which demonstrated 
decreased mechanical allodynia on the transduced side relative to the contralateral side after 
ivermectin administration. These differential effects on nociception represent the functional 
outcome of differentially targeted anti-nociceptive HSV-1 vectors and support the use of 
promoter-targeting to express transgenes in specific neuronal subpopulations. 
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1.0  INTRODUCTION 
Sensory neurons represent the initial site of contact between humans and all the various stimuli 
of the outside world.  If that contact is sufficient to generate an action potential in the neuron, 
then that stimulus has passed the first hurdle to conscious detection --- all other potential stimuli 
will go undetected.  If that stimulus is noxious, representing the extremes of temperature or the 
upper extreme of mechanical force, it triggers action potentials through specialized sensory 
neurons called nociceptors, and may ultimately result in the sensory and emotional experience of 
pain once processed by the central nervous system (CNS).  This acute pain response is adaptive, 
fostering the conscious avoidance of the source of the noxious stimulus and thereby the 
avoidance of tissue damage.  However, if this pain persists after the noxious stimulus has been 
removed and the associated tissue damage has resolved, it is considered chronic pain and is no 
longer adaptive, but pathological.  Localized chronic pain (e.g. pain persisting after tissue injury 
or focal inflammation) requires ongoing input from the peripheral sensory neurons innervating 
the site of pain.  This is evident because administration of lidocaine can be used to block action 
potential propagation in the sensory neurons, resulting in temporary abatement of chronic pain 
originating in the peripheral nervous system (PNS) [1].  The sensory neuron therefore represents 
an accessible target for therapeutic interventions to treat localized chronic pain.  Therapy 
targeting sensory neurons would have the benefit of not affecting the CNS and thereby avoiding 
the cognitive side effects of systemic opioid therapy.    Local anesthetic nerve blocks are not 
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typically used on a long-term basis due to the risk of overdose, toxicity, and the development of 
tolerance.  Therefore, there is a need to develop novel therapy to quench pain signaling at its 
peripheral source.  The ideal peripheral pain therapy would meet the following criteria: 1- Have 
an effect restricted to sensory neurons to avoid systemic and motor side effects, 2- Have no 
potential for toxicity to sensory neurons, and 3- Target the specific population of sensory 
neurons whose signaling is mediating the pain. 
 Herpes simplex virus-1 (HSV-1) vectors represent the ideal vehicle for such a 
therapeutic, because they have the advantage of specifically transducing and persisting in 
sensory neurons innervating the site of inoculation without spread to the CNS (criterion 1), and 
have no long-term neurotoxicity or oncogenic potential (criterion 2).  Furthermore, replication-
defective HSV-1 vectors have been previously used in clinical trials, demonstrating their safety 
in patients [2, 3].  Therefore, to develop HSV-1 gene therapy for chronic pain, it will be 
necessary to select an appropriate anti-nociceptive transgene to silence sensory neuron signaling 
and to target the expression of this product to the sensory neuron population responsible for the 
maintenance of pain.  In this introduction I will review the study of pain, current pain therapy 
and its limitations, the use of HSV-1 vectors for pain gene therapy, the selection of an anti-
nociceptive transgene and the choice of a relevant rodent model for this study.  
1.1 PAIN 
Pain is defined by the International Association for the Study of Pain as “An unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or described in terms 
of such damage” [4].  Chronic pain, while often initiated with nerve damage or inflammation due 
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to a trauma or infection, is recognized as a pathological process and disease separate from its 
initiating circumstances [5].  Worldwide, approximately 40% of the population has experienced 
chronic pain within the last year, with advanced age, female gender, and co-morbid depression or 
anxiety disorders being associated with higher likelihood of pain [6]. 
Chronic pain is an umbrella term encompassing a diverse set of pathologies such as pain 
localized to a peripheral site of injury or inflammation, generalized pain of CNS origin like 
fibromyalgia, and persistent headache.  It could originate from a peripheral or central lesion, or 
have large contributions from PNS, CNS, and inflammatory mechanisms, as in complex regional 
pain syndrome [7].  Also, affect and psychological state can have a significant impact on disease 
severity [8, 9]. 
Pain originating from a peripheral lesion occurs when primary afferent nociceptors are 
sensitized, resulting in hyperactive signaling (peripheral sensitization) [9].  This is in part 
mediated by the recruitment of immune cells and release of inflammatory mediators such as 
histamine, substance P, bradykinin, NGF, TNFα, prostaglandins & leukotrienes [10].  Primary 
afferent nociceptors synapse in the dorsal horn of the spinal cord to second order, wide dynamic 
range neurons.  With repetitive signaling from sensitized nociceptors, these neurons likewise 
become sensitized (central sensitization) by phosphorylation of receptors and ion channels and 
long-term changes in gene expression [9].  Additionally, microglia in the spinal cord can be 
activated by chronic nociceptor signaling, causing the release of pro-inflammatory cytokines and 
further contributing to central sensitization [11].  Peripheral and central sensitization can 
manifest not only as ongoing or spontaneous pain, but as a painful sensation arising from 
innocuous stimulation (allodynia) and increased pain in response to noxious stimulation 
(hyperalgesia) [12]. 
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At the level of the second order neuron, transmission is influenced by inhibitory 
interneurons using GABA or glycine as their neurotransmitter [13] and inhibition by endogenous 
opioids [13, 14].  These controls become impaired in the presence of chronic pain and central 
sensitization [15, 16].  Second order neurons then transduce the signal to the brainstem, 
thalamus, and from there to higher levels of the brain, including the primary and secondary 
somatosensory cortices, the insula, and the anterior cingulate cortex.  These areas have been 
termed the “pain matrix” [17] because of their demonstrated activity by functional brain imaging 
during the experience of pain [18], but may be a more general system for recognition of salient 
stimuli [19].  
While central mechanisms are of great importance to the pathophysiology of pain, this 
introduction will specifically focus on the peripheral drivers of chronic pain resulting from 
peripheral injury, inflammation, or infection.  This localized pain has the potential to be treated 
by inhibiting aberrant signaling from primary afferents directly, or by the reduction of peripheral 
inflammation. 
1.1.1 The nociceptor and PNS involvement in chronic pain. 
Sensory neurons innervating the skin are composed of a diverse population of fibers, classified 
based on diameter, myelination, conduction velocity, and neurotransmitter; and further defined 
by the expression of various sensor ion channels, making each fiber sensitive to a particular set 
of stimuli.  Given the complex sensory milieu that these neurons must contend with, this 
specialization allows for the discrimination of a broad range of mechanical and thermal stimuli 
spanning from innocuous-to-painful and hot-to-cold.  The neurons responsive to painful stimuli, 
termed nociceptors, are typically small diameter, unmyelinated, slow-conducting C-fibers and 
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lightly-myelinated, faster-conducting Aδ fibers [20].  The C-fibers can be broadly classified into 
two groups which are developmentally responsive to different growth factors and utilize different 
neurotransmitters.  The trkA-positive C-fibers are sensitive to the neurotrophin NGF and utilize 
peptide neurotransmitters, whereas the c-RET-positive C-fibers are sensitive to GDNF and 
utilize non-peptide neurotransmitters [21].   
The changes in the underlying physiology that result in the development of maladaptive 
chronic pain are complex and incompletely understood; however, different fiber types are 
implicated in chronic pain originating from different causes.  Specifically, peptidergic C-fibers 
are implicated in inflammatory pain, whereas non-peptidergic C-fibers and rapidly conducting 
mechanosensitive Aβ-fibers are implicated in pain signaling following nerve injury [12, 22-24]. 
TRPV1-positive C-fibers are responsible for the sensing of heat pain [25-27].  This can 
be experimentally assessed with the thermal withdrawal latency tests.  TRPV1-expressing 
peptidergic C-fibers also play a role in inflammatory hyperalgesia.  Furthermore, in the presence 
of persistent inflammation or following nerve injury, they contribute to progressive mechanical 
hypersensitivity [28, 29]. 
1.1.2 Pain therapy and limitations.  
Given the complex pathophysiology of chronic pain, a wide variety of drugs can be employed 
alone or in combination for therapy [8].  Among these are opioids, anticonvulsants, 
antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), cannabinoids, NMDA 
receptor antagonists, local anesthetics, capsaicin, botulinum toxin, and others [30, 31]. 
For the purpose of this introduction I will focus on the most important traditional pain 
therapeutics as grouped into four categories: (i) narcotic opioids which signal through the µ-
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opioid receptor on second order neurons to reduce pain signaling; (ii) neuromodulatory drugs 
such as anticonvulsants (gabapentin & pregabalin) and antidepressants (tricyclics & SNRIs); (iii) 
NSAIDs which function to reduce inflammation that can sensitize primary afferents; and (iv) 
nerve blocks delivering a sodium channel blocker which prevents action potential propagation, 
and/or a corticosteroid to drastically reduce inflammation, directly to a neuropathic lesion.  Each 
of these modalities has its own indications and limitations. 
Opioids prescribed for pain management are in the morphine class and are agonists of the 
µ-opioid receptor, which principally inhibit peripheral pain signaling at the level of the second 
order spinal neuron.  Opioids are the strongest systemically delivered pain medications and as 
such are widely used to treat a large variety of pain conditions [32].  Unfortunately, tolerance 
develops rapidly to their repeated use, which can lead to dependence, addiction, and withdrawal 
when discontinued.  Paradoxically, opioid use can result in increased pain levels, a phenomenon 
termed opioid-induced hyperalgesia [33].  Furthermore, as a result of systemic administration, 
opiates can cause side-effects in a diverse set of organs.  Side effects include constipation, 
nausea, orthostatic hypotension, anti-coagulation, cognitive impairments, and respiratory 
depression [34], the last of which is potentially fatal in the case of overdose. 
Gabapentin and pregabalin are often used as first-line therapy for chronic neuropathic 
pain.  Though first developed as GABA analogues and used as anticonvulsants, they have been 
widely applied to the treatment of chronic neuropathic pain [35] and for the prophylactic 
reduction in the development of post-surgical chronic pain [35, 36].  For these applications, their 
principal mechanism of action is as a ligand of voltage-gated calcium channels by binding to the 
α2-δ-1 subunit [37].  This subunit is upregulated in DRG and spinal cord after nerve injury [38] 
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and gabapentin binding results in a subsequent reduction in release of excitatory 
neurotransmitters in the dorsal horn of the spinal cord [39]. 
Antidepressants, and specifically tricyclics and selective norepinephrine reuptake 
inhibitors (SNRIs) are also prescribed as first-line therapy for neuropathic pain [8].  
Antidepressants are efficacious for the treatment of chronic pain regardless of the presence of 
comorbid depression, but would obviously have a dual benefit to depressed patients [40].  This 
hints at an alternative mechanism of action when used as a pain therapeutic, but this mechanism 
is not fully understood. 
The anticonvulsants and antidepressants are used as first-line pain therapy, but often 
require the addition of additional drugs to achieve adequate control of severe pain.  Additionally, 
not all patients tolerate the cognitive effects of these drugs. 
NSAIDs inhibit cyclooxegenase and the synthesis of prostaglandins and therefore have 
an anti-inflammatory effect.  NSAIDs can be effective in the treatment of mild to moderate pain 
resulting from inflammation, but are typically not effective in controlling severe pain or pain 
with a significant neuropathic component.  They are therefore most commonly used as adjunct 
therapy when used in these situations [41]. 
Nerve blocks [42, 43] have the benefit of being highly effective when properly placed, at 
the cost of invasiveness – requiring catheter placement into sensitive anatomy.  Therefore, they 
are usually limited to the immediate post-surgical time-frame.  Because they deliver therapeutics 
directly to the site of a neuropathic lesion, they can deliver drugs that would be toxic if taken 
systemically.  A corticosteroid is often used to control inflammation to a much higher degree 
than can be achieved by the systemic use of NSAIDs.  Furthermore, to directly inhibit action 
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potential propagation, sodium channel blockers can be used, while avoiding dangerous systemic 
side effects like interference with cardiac muscle contraction. 
For pain therapy to work optimally, any comorbid depression or anxiety should be treated 
in tandem. Furthermore, to address the higher cognitive and affective components of pain, 
mindfulness meditation, in which the patient attempts to become an observer of her own 
sensorium and thought processes, has proven to be particularly effective [44, 45].  Hypnosis may 
also be an effective adjunct pain therapy [46]. 
Despite the diverse array of available pain therapy, a large proportion of chronic pain 
sufferers have poorly controlled pain which negatively affects their quality of life [32].  Due to 
the cognitive and physiological side-effects caused by many traditional systemically-active 
therapies, many treatment options may prove intolerable.  Therefore, the development of novel 
pain therapies with greater efficacy and fewer side-effects is of critical importance. 
1.2 GENE THERAPY FOR PAIN 
Given the devastating impact of chronic pain on quality of life and the limitations of 
conventional pain therapy, there is a desperate need for new, safe, effective and long-term 
treatments.  Pain gene therapy is a relatively new treatment modality.  Of the 2142 gene therapy 
clinical trials to date since 1989, 39 have been indicated for neurological diseases, and of that, 
two have been indicated for pain [47]. 
Gene therapy has the potential to deliver one or several gene products directly to the 
relevant anatomical location [48, 49].  Once delivered, the genes could continuously generate 
products over the long-term, as demonstrated with HSV-1 vectors [50, 51]. 
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Gene therapy has the potential to overcome each of the limitations of conventional 
therapy.  By shifting the paradigm from small molecules delivered systemically to the targeted 
expression of anti-nociceptive genes directly to the source of aberrant pain signaling, gene 
therapy can both avoid systemic side-effects (especially of opioids) and concentrate potent 
neuromodulatory or anti-inflammatory products directly to their site of action to maximize 
therapeutic efficacy.  For instance, gene therapy can be used to express a potent anti-
inflammatory cytokine to control local inflammation without compromising systemic immunity, 
or an endogenous opioid without engendering tolerance [49, 52].  Alternatively, gene therapy can 
achieve nerve block without the necessity (and risk of systemic toxicity) of sodium channel 
blockade and without the risk of neuronal damage by the invasive placement of catheters [53]. 
1.2.1 HSV-1 vectors. 
After inoculation on broken skin or at mucous membranes, HSV-1 undergoes lytic replication in 
fibroblasts and epithelial cells.  As large numbers of virions accumulate at the inoculation site, 
particles adsorb at sensory nerve termini and infect the neuron.  Particles are then transported 
retrograde to the neuron cell body in dorsal root ganglia (DRG) or trigeminal ganglia (TG) where 
the viral genome is delivered into the nucleus [54].  In neurons, productive replication is limited 
and the genome enters a latent state, characterized by minimal transcription of viral genes.  
During latency, the HSV-1 genome is circularized and heterochromatinized.  One non-coding 
gene product is expressed in a fraction of transduced neurons: the latency associated transcript 
(LAT).  The function of LAT is controversial, generating two stable introns and several 
microRNA species, but LAT-deleted viruses are impaired in reactivation efficiency [55].  
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Furthermore, the LAT promoter sequences, active in neurons, have been used to drive long-term 
expression of transgenes in the CNS [50] and PNS [51]. 
To generate HSV-1 vectors for gene therapy [56, 57], one common strategy to render 
HSV-1 replication-defective is to introduce deletions into one or both of the essential immediate 
early genes ICP4 and ICP27.  The resultant recombinant vectors are unable to progress beyond 
the immediate early stage of gene expression unless grown in cells complementing these 
deletions [58].  This is often paired with the deletion of the internal repeat region, which prevents 
isomerization of the genome, as well as eliminating one copy of immediate early genes ICP0 and 
ICP4 and reducing expression of ICP22.  This further reduces viral gene expression without 
overly compromising vector yield [59]. 
HSV-1 vectors are currently viewed as a niche vector in the field of gene therapy, 
accounting for only 3.1% of clinical trials [47].  This is in large part due to practical concerns, 
with the large size of the HSV genome (~152 kilobase-pairs) making vector engineering a more 
technically involved process, carried out through homologous recombination in cell culture or 
through manipulation of the vector propagating as a bacterial artificial chromosome (BAC) in E. 
coli [60].  Furthermore, the larger size results in a greater probability of off-site mutations 
accumulating through the process of vector engineering.  Therefore, HSV-1 vectors are chosen 
over their more widely used alternatives only for applications where HSV has a significant 
advantage in transduction efficiency.  In other words, HSV-1 vectors are used almost exclusively 
for the transduction of neurons and have a particular advantage in the transduction of primary 
afferents, where the use of other vectors typically necessitate the direct injection of high titers 
directly into sensory ganglia [61]. 
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The large size of HSV-1 vectors, most of which contain large deletions (e.g. the 
commonly deleted internal repeat is ~15 kilobase-pairs), also significantly increases the carrying 
capacity.  Therefore, HSV-1 vectors can accommodate very large or multiple transgenes.  
Relevant to this study, the inclusion of large genomic promoter sequence for the purpose of 
achieving endogenous expression activity is possible with HSV-1 vectors. 
1.2.2 Anti-nociceptive transgenes. 
Six general strategies have been used to treat pain with HSV vectors: (i) expression of the 
endogenous opioids, preproenkephalin (PPE) [2, 3, 62-75] & endomorphin [76, 77] for tonic 
analgesia, (ii) expression of glutamic acid decarboxylase (GAD) to increase GABA-mediated 
inhibitory tone [2, 78-81], (iii) expression of interleukins to reduce inflammation [82-84] and 
inversely, of a soluble TNFα receptor to decrease TNF signaling [85], (iv) expression of 
neurotrophins to promote neuronal survival [86-91], (v) knockdown of pain-induced sodium 
channel subunit NaV1.7α, and (vi) expression of the inhibitory ion channel GlyR for targeted 
neuronal silencing [53], as used in this study.  
1.2.3 Endogenous opioids: Preproenkephalin A (PPE) & endomorphin. 
PPE is the precursor to the endogenous opioids Met- & Leu-enkephalin which signal principally 
through delta opioid receptors [14].  It was the first transgene tested [92] and the transgene with 
the most extensive history of use for anti-nocieptive activity in animal models [49].  It is also the 
only one tested in clinical trials [2, 3] for the treatment of pain with HSV-1 vectors.  By 
expressing PPE in sensory neurons, enkephalins can act directly on nociceptors themselves in an 
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autocrine or paracrine manner, or be released into the synapse with the second order neurons in 
the dorsal horn of the spinal cord to limit pain transmission higher up the neuraxis.  Extensive 
studies using HSV-expressed PPE have been conducted on rodent pain models as well as in 
primates and clinical trials. 
In rodents, the expression of PPE from HSV-1 vectors has been effective in reducing pain 
behavior in models of inflammatory pain, neuropathic pain, visceral pain, and specific disease 
models.   
Inflammatory pain models --- 
PPE driven from the cytomegalovirus immediate early promoter (CMV) demonstrated 
greatly reduced thermal hyperalgesia following capsaicin or DMSO induced hypersensitivity, 
while baseline thermal responses were unaffected [64].  PPE also reduced pain behavior in the 
formalin test of inflammatory pain, an effect that could be blocked with opioid receptor 
antagonist naltrexone [65].  A study on chemically induced polyarthritis demonstrated increased 
locomotion, lower hyperalgesia, and less bone destruction with the use of the PPE vector [66].   
Neuropathic pain models --- 
PPE expression was able to reduce open field pain scores from a bone cancer pain model 
[62].  A study looking to more extensively characterize the effect of PPE in a neuropathic pain 
model demonstrated that PPE expression prevented pain-induced c-fos expression in the dorsal 
horn [63].  PPE expression worked synergistically with morphine, lowering the ED50 by ten-fold, 
and the anti-nociceptive effect of PPE was maintained even after tolerance was induced to 
morphine [63].  To study PPEs effect in a long-term pain model, pertussis toxin was injected 
intrathecally in mice and PPE expression was able to reverse the induced thermal hyperalgesia 
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for up to six weeks [67].  Two studies on trigeminal neuropathic pain [69] or myogenic orofacial 
pain [75] demonstrated lowered pain scores with PPE expression.   
Visceral pain models --- 
Two studies using a model of bladder hyperactivity and pain demonstrated naloxone-
reversible reduced pain behavior following the intrabladder injection of capsaicin [70] or 
resiniferatoxin [74].   
Specific disease models --- 
Two studies have assessed PPEs effects on a rat model of pancreatitis [71, 72]. The first 
demonstrated increased spontaneous behavior, preservation of cellular architecture, and reduced 
inflammatory infiltrates in the pancreas [71] and the second study demonstrated a normalization 
of hot-plate sensitivity and prevention of fos induction in the dorsal horn [72].  One study using a 
model of painful diabetic neuropathy found that the expression of PPE could reduce the induced 
expression of the NaV1.7 sodium channel in primary afferents and fos induction in the dorsal 
horn, as well as lowering pain behaviors [68].  Also, the expression of PPE was able to prevent 
the development of hypersensitivity in a model of post-herpetic neuralgia [93]. 
A primate study [73] in Macaques demonstrated an anti-hyperalgesic effect of PPE to 
repeated thermal and chemical stimulation that lasted up to 20 weeks after injection of the HSV-
1 vector in the dorsal surface of the foot. 
Finally, an HSV-1 vector expressing PPE has been tested in a phase I and ongoing phase 
II clinical trial [2, 3] for intractable focal pain caused by cancer in terminal patients.  The phase I 
trial demonstrated the safety of this approach, with no serious adverse events reported.  It also 
provided promising preliminary data on efficacy.  Subjects receiving the higher vector doses 
(three patients per group receiving 108 or 109 pfu) reported lower pain scores throughout the 
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study.  Those patients surviving to the trial’s final time-point of 28 days post-injection had pain 
scores that had risen from their nadir, but had not returned to pre-injection levels [3]. 
Related to this approach is the expression of a synthetic gene producing the endogenous 
opioid endomorphin, which signals through µ-opioid receptors.  Endomorphin expression 
reduced pain responses in both neuropathic [76] and inflammatory pain models [77]. 
Despite the impressive collection of anti-nociceptive data generated using PPE or 
endomorphin, endogenous opioids were not selected for this study because they can act in a 
paracrine manner on nearby neurons in the DRG and across the synapse with second order 
neurons, and therefore are unsuitable for targeted neuronal silencing.  
1.2.4 Glutamic acid decarboxylase (GAD). 
GAD catalyzes the rate limiting step in GABA synthesis.  Its production by HSV-1 vectors 
serves to increase levels of the inhibitory neurotransmitter GABA to inhibit pain signaling 
through second order neurons in the spinal cord. 
With increased nociceptive input from peripherally sensitized nociceptors, there is a 
decrease of spinal inhibitory GABAergic tone and reciprocal increase in excitatory glutamatergic 
tone [94].  GABA is biosynthesized from glutamate by GAD, so by increasing GAD levels, gene 
therapy can shift the balance from glutamate-mediated excitation to GABA-mediated inhibition.  
GAD expression reduced pain measures in several neuropathic pain models including spinal cord 
hemisection [81], spinal nerve ligation [78], lumbar radiculopathy [95], and painful diabetic 
neuropathy [79] where it also prevented increase in NaV1.7 levels.  Furthermore, GAD 
expression was demonstrated to be more effective than PPE in reducing pain responses in the 
streptozotocin model of painful diabetic neuropathy [96]. 
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Like PPE, the mechanism of action of GAD expression is through the secretion of a 
soluble mediator (in this case GABA), and therefore unsuitable for targeted neuronal silencing. 
1.2.5 Anti-inflammatory interleukins and the TNFα receptor. 
Inflammation can sensitize primary afferents causing increased spontaneous activity and lowered 
thresholds to generate action potentials, leading to the development of chronic pain.  One general 
strategy to treat inflammatory pain is to express anti-inflammatory cytokines such as IL-4, IL-10, 
or IL-13 to reduce inflammation, or a soluble TNFα receptor to reduce TNFα-mediated 
inflammatory signaling.  IL-4 [82] and a soluble TNFα receptor [85] expressed from HSV-1 
vectors have reduced pain behaviors in a neuropathic pain model.  Expression of IL-10 decreased 
pain behaviors in the formalin test of inflammatory pain [83] and reduced TNFα production from 
activated microglia in vitro. 
Use of anti-inflammatory cytokines may be ideal for the reduction of inflammation in 
inflammatory pain or at the site of a neuropathic lesion in a manner akin to the anti-inflammatory 
component of a nerve block. 
1.2.6 Pro-survival factors: NT-3,  NGF, VEGF, & EPO. 
For the treatment of diabetic or chemotherapy-induced polyneuropathy, growth factors can be 
expressed from HSV-1 vectors to serve as pro-survival signals to affected afferents.  In these 
experiments HSV-1 vectors are injected prior to the induction of neuropathy to assess a 
protective effect.  In pyridoxine-induced neuropathy, a protective effect was demonstrated for 
neurotrophin-3 (NT-3) [97] and nerve growth factor (NGF) [87].  The effect from NGF 
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expression could be sustained to six months by the use of HSV-1 LAP2 to drive long-term 
expression [51].  Similarly, expression of NT-3 or NGF protected against cisplatin-induced 
neuropathy [88]. 
In the streptozotocin model of painful diabetic neuropathy expression NGF [86], VEGF 
[98], NT-3 [89], and EPO [90] were protective.  The EPO expressing vector, originally using the 
CMV promoter to drive transgene expression, was subsequently modified to make it 
doxycycline-inducible [99]; and then finally modified for prolonged, regulated expression using 
a doxycycline-inducible LAP2 promoter [91]. 
Use of pro-survival factors may be ideal for the prevention of painful diabetic neuropathy 
or chemotherapy-induced polyneuropathy.  Prophylactic treatment is feasible in both cases as it 
can be administered prior to chemotherapy or early in the course of diabetes, before the 
development of neuropathy.  
1.2.7 Knockdown of NaV1.7α. 
NaV1.7 was strongly implicated in pain by the identification of disease-causing mutations 
resulting in primary erythermalgia [100, 101], a painful inherited neuropathy, and paroxysmal 
extreme pain disorder [102].  The pore-forming α-subunit of NaV1.7 is upregulated in the 
context of streptozotocin-induced painful diabetic neuropathy [103], influencing electrical 
properties of primary afferents and contributing to peripheral sensitization.  Two groups have 
used HSV-1 vectors to knockdown levels of NaV1.7α [104, 105].  The first expressed an 
antisense sequence and demonstrated a reduction in inflammatory hyperalgesia [105].  The 
second used an miRNA approach and demonstrated pain reduction in a model of painful diabetic 
neuropathy [104]. 
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Knockdown strategies have the potential to be combined with transcriptional or 
transductional targeting strategies (discussed below) to achieve targeted knockdown of 
inflammatory or nosogenic products. 
1.2.8 Glycine receptor (GlyR) and ivermectin sensitive mutant GlyRIS. 
The glycine receptor (GlyR) is a ligand-gated chloride channel activated by glycine and 
expressed in the CNS, but not in the PNS.  Its activation in the spinal cord and brainstem results 
in inhibition of action potential generation.  Additionally, the absence of endogenous GlyR in the 
PNS means that the application of glycine after vector delivery would have an effect limited to 
vector-delivered channels.  For these reasons it was an attractive candidate for peripheral 
neuronal inhibition. 
GlyRs are pentamers composed of two of four possible GlyRα subunits and three GlyRβ 
subunits [106].  For transgene purposes, it has been demonstrated that receptors formed as a 
homopentamer of GlyRα1 are fully functional [107-111]; therefore, this subunit can be expressed 
from gene therapy vectors as a stand-alone anti-nociceptive transgene. 
Early studies of HSV-delivered GlyR in rats demonstrated reduced thermal and operant 
pain scores in inflammatory pain models and reduced pain scores in a bladder model of visceral 
pain [53], providing proof of principle for nociceptor silencing using this approach. 
This study employs an ivermectin-sensitive variant of GlyR [112], herein referred to as 
GlyRIS, in which two point mutations have been introduced, changing its ligand from glycine 
(which is not bioavailable if taken orally, and may be present in the PNS milieu) to the FDA-
approved [113] anti-helminthic drug ivermectin.  This was done to increase the clinical relevance 
of these vectors by allowing for the future use of orally delivered ivermectin with the intention 
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that it would specifically activate the vector-delivered GlyRIS channels without off-target effects.  
However, the study described herein uses local injection of ivermectin, not oral or systemic 
delivery. 
1.2.9 Targeting transduction and transgene expression. 
Extensive progress has been made on vector targeting, following the principle of limiting the 
effect of vectors to the set of cells necessary for the desired therapeutic outcome, and thereby 
increasing both safety and efficacy.  In general, this can be achieved on three non-mutually 
exclusive levels.  The first is the choice of the viral vector, with each species possessing a degree 
of tropism or evolved preference for certain cell types within the body (in the case of HSV, for 
sensory neurons).  The second is the engineering of receptor-binding proteins on the vector’s 
surface to direct attachment and entry to a desired cell type (transductional targeting).  And the 
third is on the level of gene expression (transcriptional targeting). 
Transductional targeting was first achieved by pseudotyping, or the exchange of surface 
proteins for those of another virus to adopt its entry mechanism.  This was classically done with 
the VSV-G glycoprotein to take advantage of its broad tropism [114].  Transductional targeting 
has become more sophisticated by generating recombinant viral surface proteins to alter receptor 
binding.  This can be done by directed evolution of a vector with a broad tropism towards 
specificity for a chosen cell type within its existing repertoire [115-117], by the introduction of 
point mutations to eliminate receptor binding [118, 119], or the rational engineering of viral 
surface proteins to replace native receptor-binding domains with novel ones [119].   
Transductional targeting has been employed on HSV-1 vectors.  To accomplish this, 
mutations are made in gD, the glycoprotein which binds to HSV-1 receptors HVEM and nectin-1 
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[120].  By introducing mutations to eliminate HVEM and nectin-1 binding and then introducing 
the sequence for the variable region of a single chain antibody, HSV-1 entry was redirected to 
use the epidermal growth factor receptor [119]. 
Transcriptional targeting, also referred to as promoter-targeting, relies on the use of cell 
type-specific promoter elements to drive transgene expression in the subpopulation of transduced 
cells in which the promoter is endogenously active, based on the cellular epigenetic and 
transcription factor milieu [121].  This strategy is the most flexible, allowing the targeting of a 
cell type on the basis of the expression of a marker gene of the investigator’s choosing.  This is 
particularly useful when targeting expression to neurons, as neuronal populations can be 
classified by a wide variety of factors, including, fiber size, conduction velocity, neurotransmitter 
expression, receptor expression, and the presence of electrophysiologically distinct currents 
based on the presence of certain ion channels [122]. 
For the development of gene therapy, promoter-targeting has been used to target a diverse 
range of cell types in tissues throughout the body, including extensive work in neuronal targeting 
in the CNS [123]. 
Transcriptional targeting of HSV-1 vectors has focused on the development of oncolytic 
therapy.  The HSV-1 essential gene encoding ICP4 was engineered to target expression to 
albumin-expressing cells to limit HSV-1 replication to this cell type [124].  More recently, HSV-
1 was transcriptionally targeted to replicate in prostate tumors, using a prostate-specific promoter 
driving the essential gene encoding ICP27, in combination with transductional targeting [125].  
Another study characterized eight promoters whose genes were highly expressed in 
hepatocellular carcinoma (HCC) by microarray and used them to express a marker gene from 
HSV-1 vectors in HCC in vitro and in vivo [126]. 
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Finally, to further target gene expression, HSV-1 vectors have also employed miRNA 
recognition sequences to limit expression in off-target cell types [127]. 
This study uses the flexibility of transcriptional targeting, allowing for the selection of 
target neurons based on the expression of a marker gene.  We use the TRPV1 promoter to drive 
GlyRIS expression in heat sensitive nociceptors, and we use the heavy neurofilament (NF200) 
promoter to drive expression in large diameter Aβ-fibers. 
1.3 PAIN MODELS & TESTS OF NOCICEPTION 
The definition of pain (“An unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage” [4]) includes an affective 
component – “unpleasant”, “emotional” – and alternatively, relies on a subjective description.  
This immediately presents two obstacles to the creation of rodent models of pain: the obvious 
difficulty in assessing a rodent’s affect, and the inability of a rodent to provide a description.  
Given these limitations, the tests used to assess pain in rodents are more precisely tests of 
nociception, defined as the neural process of encoding stimuli that are damaging or threaten 
damage to normal tissues. 
Noxious stimuli evoke a defensive response in rodents (e.g. a tail flick, paw withdrawal, 
escape behavior, etc.) and tests are designed to quantify the presence or frequency of responses, 
or latency until such a response is observed.  When a noxious stimulus is used, greater or earlier 
responses from test animals are defined as hyperalgesia.  Allodynia, on the other hand is the state 
in which stimuli that are normally innocuous are perceived as noxious and elicit a response.  
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Nociceptive tests can be conducted on naïve animals or on animals that have been genetically, 
surgically, chemically, or virally manipulated to induce pain. 
Tests of nociception have a long history of use and have been the subject of several 
review articles [128-130].  They can be either tests of evoked responses or measures of ongoing 
or spontaneous activity (e.g. place preference tests).  Tests used to evoke a nociceptive response 
are typically grouped according to the type of stimulus used: mechanical, thermal, and electrical.  
Electrical stimulation activates fibers non-specifically and has limited clinical applicability, so I 
will focus attention on the former two.  Mechanical and thermal stimuli are detected through 
activation of distinct receptors (mechanoreceptors and thermoreceptors) and clinically, 
mechanical or thermal allodynia or hyperalgesia may result depending on the specific pain 
syndrome.  Ideally, pain experiments should be designed to closely model the clinical pain 
syndrome being studied and tests of nociception should be used in accordance with the pain 
outcomes of interest. 
Most pain models fall into the categories of surgical injury or chemical irritation [131].  
When selecting a pain model, an investigator will likely consider the extent of historical use of 
the model (i.e. “gold standard” models) allowing the investigator’s study to be compared to a 
wide variety of other experiments using the same model.  Another consideration is the clinical 
relevance of the model.  These are often competing interests, with models such as the formalin 
test having extensive historical use and yet being highly contrived with limited clinical 
relevance.  Finally the investigator will account for any particular considerations of their 
experiment that may necessitate the use of one model over another.  In this section I will focus 
on models of superficial pain corresponding to the sensory neurons in which HSV-1 establishes 
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latency in its viral life cycle; however, HSV-1 vectors have also been used to treat visceral [53] 
and cancer pain [2, 3].  
1.3.1 Pain models. 
Surgical pain models involve ligating or transecting nerves at established locations to result in 
pain localized to the region innervated distal to the nerve injury.  Common surgical models of 
PNS pain in order of most proximal to most distal down the neuraxis (corresponding to greater to 
more limited pain outcomes) are: (i) spinal nerve ligation (SNL), in which L5 (with or without 
L6) spinal nerve(s) are tightly ligated [132]; DRG compression by insertion of a metal rod into 
the L5 intervertebral foramen [133]; chronic constriction injury (CCI) in which loose ligatures 
are bound around the common sciatic nerve [134]; partial nerve injury in which one third to one 
half of the sciatic nerve is ligated [135, 136]; and spared nerve injury (SNI), in which the tibial 
and common peroneal branches of the sciatic nerve are lesioned, sparing the sural nerve [137].  
Each of these models results in a well-established pain outcome resulting from the Wallerian 
degeneration of constricted or ligated nerve fibers. 
Disease models attempt to recapitulate a particular human disease in animals and may or 
may not use the agent of human disease.  For instance, the models for chemotherapy-induced 
polyneuropathy involve administering a large dose of the chemotherapy agent, such as 
pyridoxine [51, 87, 97] or cisplatin [88].  Similarly, post-herpetic neuralgia, occurring in humans 
after a VZV viral reactivation event, is induced in rats by the injection of VZV-infected cells 
[93].  Other disease models use an agent which will damage the correct tissue to simulate the 
disease.  The most widely used model in this category is the use of streptozotocin, a compound 
toxic to pancreatic β-cells, to model diabetes and its sequella: painful diabetic neuropathy [86, 
 22 
96, 138].  Another disease model of this type involves the use of Freund’s adjuvant to induce 
polyarthritis in rodents, to model rheumatoid arthritis [66]. 
 Chemical pain models utilize compounds which cause inflammation, damage to neurons, 
or directly activate ion channels, causing pain.  Inflammatory compounds can be injected under 
the skin of the plantar surface of the hind footpad.  The most common compounds used are 
complete Freund’s adjuvant (CFA) [139], zymosan [140], carrageenan [141], and bee venom 
[142].  Other compounds such as serotonin, bradykinin, prostaglandin E2, substance P and 
histamine can also be used [143].  Formalin is a commonly used reagent to induce inflammation 
and directly damage nerve fibers and has the longest history of use [144-146].  Capsaicin can be 
used to activate TRPV1 channels, causing increased signaling through heat-sensitive nociceptors 
and lowered thermal withdrawal thresholds [147]. 
 Resiniferatoxin (RTX) irreversibly activates TRPV1 channels resulting in an influx of 
cytotoxic amounts of calcium and death of the neuron.  Therefore early applications of RTX 
focused on its ability to chemically ablate the TRPV1+ neuronal population.  Being that TRPV1 
is the receptor for noxious heat, after RTX ablation of TRPV1+ nociceptors thermal tests of 
nociception show dramatic desensitization to heat as evidenced by increased thermal withdrawal 
thresholds [148]. 
Subsequently, it was observed [149] that by 20 days following systemic RTX 
administration, mechanical thresholds were paradoxically lowered.  In other words, animals were 
experiencing RTX-induced mechanical allodynia.  The first study to demonstrate this, also found 
evidence of inflammation along the length of the nerve, developing over the same time-frame 
[149].  It is theorized that this inflammation is secondary to the Wallerian degeneration of killed 
TRPV1+ nerve fibers and sensitizes the remaining large diameter Aβ-fibers. 
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This study takes advantage of this time-dependent, reciprocal effect (early, sustained 
increase in thermal thresholds due to TRPV1+ neuron ablation and late decrease in mechanical 
thresholds due to inflammation), to demonstrate a functional consequence of differentially 
targeted anti-nociceptive vectors.  Specifically, the use of RTX tests the hypotheses that: 
1- An anti-nociceptive effect targeted to TRPV1+ neurons will no longer be significantly 
different from other groups when all TRPV1+ neurons are ablated by RTX, and  
2- An anti-nociceptive effect targeted to large, NF200-rich, mechanosensitive fibers will 
reduce the degree of mechanical allodynia caused by RTX-induced inflammation. 
1.3.2 Thermal tests.  
The classic thermal tests use latency before a withdrawal response from a noxious thermal 
stimulus as their metric.  Hyperalgesia is therefore indicated by a reduction in withdrawal 
latency.  These tests include the tail flick test (measuring latency until tail flick – a spinal reflex – 
after submerging in hot water or with exposure to radiant heat) [150], hot plate (latency until paw 
licking once placed on a 52oC or 55oC plate) [151, 152], cold plate (scoring of nociceptive 
behaviors over time) [134, 153], and the Hargreaves radiant heat apparatus test in which latency 
is timed from the application of a radiant heat source to the paw withdrawal reflex, once the rat is 
acclimated to a heated platform [154].  The Hargreaves test was selected for this study based on 
its reliable assessment of changes to TRPV1+ neuron function and high reproducibility do to 
ease of use. 
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1.3.3 Mechanical tests. 
Around the turn of the 20th century, the Austrian-German physiologist Maximilian von Frey 
developed a methodology for exerting a consistent force to a punctate area of the skin.  He 
utilized hairs of various thicknesses mounted on the ends of handheld applicators – the thicker 
the hair, the more force it would take to bend [155].  Thereby, the minimal threshold force/hair 
thickness to elicit a sensation could be assessed.  Such implements were eponymously named 
von Frey hairs, and have kept this name to the present day despite the hair being replaced by the 
use of nylon monofilaments [156], which exert precisely calibrated gram weights when bent.  
Using von Frey hairs to determine the force threshold to elicit a withdrawal response from the 
hind paw of naïve rodents, one can assess whether a test rodent withdraws at a lower force when 
subjected to a pain model, evidencing mechanical allodynia.  A common, efficient procedure to 
assess withdrawal thresholds and mechanical allodynia with von Frey hairs, termed the “up-
down method”, uses hairs of increasing force until withdrawal is elicited, then reducing the force 
and oscillating around the withdrawal point to determine a pattern from which withdrawal 
thresholds can be calculated [157]. 
The von Frey test has demonstrated a wide range of thresholds between experimenters, 
which limits extrapolation of thresholds between labs.  However, there is high reproducibility 
within experiments.  This reflects the fact that there are small variations between testing 
conditions (e.g. angle of application, degree of filament bending, and duration of application), 
which ultimately requires rigid consistency in protocol by the experimenter to control for these 
variances.  In an intensive review of the causes of inter-experimenter differences in von Frey 
responses [158], Bove postulated that the ideal mechanical stimulator should apply force along a 
single axis (bending of filaments causes off-axis forces), via a standardized blunt transducer (not 
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variably sized cylindrical filaments), applied independent of the relative movements of 
experimenter and subject, across a continuous range of pressures instead of discrete intervals, 
and that the experimenter should be blind to the force necessary for withdrawal to avoid bias 
[158].  Recently, automated von Frey systems have been developed which address some of these 
concerns.  The electronic von Frey developed by Ugo Basile [159] uses a continuous scale, 
experimenter blind approach and the electronic von Frey developed by Somedic [160] uses an 
inflexible tip to standardize the transduction surface.  Additionally, as Bove commented in his 
review, many of the conditions of an ideal stimulator are met by another mechanical test, the 
Randall-Selitto paw pressure test.  This study, however, will employ traditional von Frey 
monofilaments using the quantitative “up-down method” due the lab’s technical expertise with 
this procedure and its extensive historical use [157, 161]. 
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2.0  MATERIALS AND METHODS 
2.1 VECTORS 
Neuronal promoter-targeted vectors and mCherry-expressing test vectors were generated from 
the vL vector backbone, which was specifically designed for this experiment.  The vL backbone 
was generated from DBAC [162], which was engineered from the HSV lab strain KOS in which 
BAC sequences were inserted into the TK locus by homologous recombination in cell culture.  
Further modifications were introduced by RedE/T mediated homologous recombination in E. 
coli [60].  Deletions were introduced in the genes encoding immediate early proteins ICP4 and 
ICP27, rendering the vector replication-defective [58, 163].  Further alterations were made from 
the DBAC vector.  First, the internal repeat sequence was deleted, and the promoter for ICP27, 
which was deleted from its native locus, was reintroduced to drive ICP22, the promoter of which 
was part of the deleted repeat sequence.  The Gateway destination cassette was inserted into the 
remaining latency locus, replacing the latency promoter elements while maintaining a wild-type 
copy of ICP0 and the surrounding CTCF chromatin boundary elements [164, 165].  To generate 
targeted expression vectors, transgenes were cloned into a modified pENTR1A plasmid, 
containing attL sites for recombination with the attR-containing vector backbone using the 
Gateway LR Clonase II enzyme mix (Life Technologies). 
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pENTR1A was modified to delete the CCDB gene and insert the highly-stable αGlobin 
3’UTR [166, 167] and SV40 polyadenylation signal.  A PmeI linker was inserted into the DraI 
site, upstream of the ORF insertion site, so that this 8bp restriction site would remain unique 
after the insertion of the GlyRIS or mCherry ORF.  Transgene ORFs were amplified by PCR 
using a forward primer incorporating a Kozak consensus translation initiation sequence and then 
inserted into the unique HincII site of this vector.  Each of the above elements was confirmed by 
sequencing.  Finally, the promoters were inserted into the unique PmeI site as blunt-end digest 
fragments from other plasmids of known sequence. 
In selecting the promoter sequences for the TRPV1 and NF200 promoters used in this 
study, we included previously characterized promoter elements.  A 1,284 base-pair sequence 
corresponding to the TRPV1 dual promoter sequence defined by Xue et al. [168] was selected to 
target expression to heat-sensitive C-fiber nociceptors.  For the NF200 promoter, a 970 base-pair 
sequence surrounding the core promoter elements was purchased from SwitchGear Genomics 
(Carlsbad, CA) [169], as was the 932 base-pair CGRP promoter [170].  The CMV promoter 
[171] was isolated from pEGFP-N1 (Clontech) as a 555 base-pair fragment by digestion with 
AseI and AfeI.  The HSV-1 latency promoter region was amplified out of KOS DNA using the 
primers: gtctgatacccatcctacacc & gtctttgttgaacgacaccg.  The sequences used for the CMV 
promoter, NF200 promoter, TRPV1 promoter, GlyRIS ORF and pENTR1A-derived pEPαGpA 
multiple cloning site can be found in Appendix A. 
The control vector expressing GlyRIS from the CMV promoter was generated from the 
vH backbone [172], which has served as the basis for previous animal studies [53, 74, 93] and is 
closely related to the vector used in ongoing clinical trials [2, 3].  vH like vL is a KOS-based 
vector, deleted for the internal repeat region, ICP4 and ICP27 [58, 163].  Unlike vL, all 
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modification to vH have been made by homologous recombination in cell culture and as such it 
contains no BAC sequence. vH also differs in that the promoters for immediate early genes 
ICP22 and ICP47 have been modified to change them from immediate early to early expression 
kinetics.  Finally, vH differs in the location of the transgene insertion site, with CMV-GlyRIS 
inserted into both ICP4 loci instead of the LAT locus. 
2.1.1 Vector diagnostics and preparation. 
Vector clones were subjected to a series of diagnostic tests.  First, vector DNA was digested with 
MfeI to validate genomic integrity.  PCR amplification across the transgene insertion site was 
then carried out and amplicons of the correct size are sent for sequence confirmation.  Once the 
sequence was confirmed, vectors generated in E. coli were tested for growth by transfecting 
(Lipofectamine LTX, Invitrogen) purified vector DNA into 7b cells, a Vero cell line expressing 
ICP4 and ICP27 to complement vector deletions of these genes [58, 163].  Clones that pass each 
of these quality control measures were further amplified on 7b cells, in DMEM (with glucose, 
glutamine and sodium pyruvate, Corning 10-013-CV) supplemented with 2.5% FBS. 
The vector was harvested by adding a 5M NaCl PBS solution (Sigma) to the medium to a 
final concentration of 450mM NaCl and left on a rocker at ambient temperature for 1 hour to 
dissociate cell-bound virions.  Any cells that remained attached to the cell culture flask were 
scraped and the medium was transferred to 50mL conical tubes and centrifuged for 10 minutes at 
2,500 rpm at 4oC.  Supernatant was then subjected to filtration using a 0.8µm filter (Nalgene 
125-0080) to remove microscopic cellular debris.  The filtrate was added to sterile autoclaved 
30mL Oak Ridge high speed centrifuge tubes (Nalgene 3114-0030) and centrifuged at 44,000 xg 
for 45 minutes at 4oC to precipitate virions.  Depending on the scale of the preparation, the 
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supernatant was decanted and additional 30mL volumes of filtrate were added to the same tubes 
and the centrifuge step repeated.  The supernatant was carefully removed by decanting and 
aspirating the inverted tube and 10mL of PBS was added to the tubes and centrifuged at 44,000 
xg for 20 minutes.  This fluid was removed and 150uL of PBS was carefully pipetted onto the 
pellet, which was left to resuspend overnight at 4oC.  The next day, sterile glycerol was added to 
a final concentration of 10% and the mix was gently pipetted up and down until the pellet and 
glycerol were homogenized.  The resultant vector prep was aliquotted into cryovials and sealed 
into a Styrofoam rack and placed into a -80oC freezer.  After at least 24 hours, one of the aliquots 
was thawed on ice for titration on complementing cells.  A series of 10-fold vector dilutions were 
made in serum free DMEM (Corning 10-013-CV) in duplicate and used to infect monolayers of 
7b cells on 48-well plates (BD Falcon 353230).  After a two hour incubation at 37oC, 10% 
methylcellulose in DMEM was added to the wells to limit viral diffusion and the plates were 
returned to the incubator.  Approximately 48 hours later (the time varies with the viral vector 
backbone being grown), this media was aspirated and a solution of 0.5% (w/v) crystal violet and 
0.2% (w/v) sodium acetate solution in 10% ethanol (pH=3.6) was added to each well and 
allowed to sit for 10 minutes at ambient temperature.  The stain was then removed and the plate 
was washed with water and allowed to dry.  Plaques (clearings of infected cells on the stained 
monolayer) were counted (between 10-100 plaques in the most dilute wells), averaged between 
duplicates and the concentration of the original aliquot in plaque forming units (pfu) per mL was 
calculated. 
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2.2 DRG CELL CULTURE EXPERIMENTS 
Sprague-Dawley rat embryos (Charles River, Wilmington, MA) were harvested at day 16 at 
which point their DRG are just developed to the extent that they are easily removed.  Total DRG 
were combined and digested in a solution of 0.25% trypsin-EDTA (Gibco 25200) in neurobasal 
media (Gibco 2103) for 1 hour and gently pipetted up and down to dissociate them.  Cells were 
centrifuged out of solution at 1,200 rpm for 3 minutes and washed three times with neurobasal 
media to remove all traces of trypsin.  Finally, the cells were resuspended in neurobasal media 
warmed to 37oC with 1X B27 supplement (Gibco 17504) and 50ng/mL NGF (Promega G5141).  
DRG cells were plated at 105 cells per well onto coverslips that had been coated in 100ug/mL 
poly-D-lysine (Sigma P6407) in water for 2 hours at ambient temperature and placed in 24-well 
plates until completely dry.  Cells were incubated at 37oC and 5% CO2 for 1-2 weeks prior to 
transductions, with 50% of the media volume replaced every 7 days with fresh media.  To limit 
glial overgrowth, the anti-mitotic FUdR (Sigma F0503) was added to the media at 10uM at the 
first media change and washed off 24 hours later with fresh media [173]. 
DRG cells were transduced with 3x105 pfu of vectors, corresponding to an approximate 
MOI of 3 relative to the number of cell originally plated (glial cell expansion and death from 
FUdR makes this approximate).  Transduction took place over a 1 hour incubation time at 37oC 
after which the transduction media was exchanged for fresh media.  After 48 hours, the cells 
were imaged for red fluorescence from mCherry expression on a Nikon Eclipse Ti-S/L100 with a 
Xenon Arc bulb (20110801) at a constant exposure time.  Using Metamorph software, composite 
images were generated overlaying red fluorescent images with bright-field images. 
For NF200 immunofluorescence, after the 48 hour incubation, wells were rinsed with 
PBS and then fixed in 2% buffered formalin solution in PBS for 10 minutes.  Three rinses with 
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PBS were conducted, allowing each PBS rinse to equilibrate for 5 minutes.  For blocking, a 
solution of 5% normal goat serum (Sigma) in PBS was used for 1 hour at ambient temperature.  
After three rinses, the primary rabbit polyclonal antibody against NF200 (Abcam ab8135) was 
added at a concentration of 1:1000 in blocking solution and left overnight at 4oC.  The following 
day, antibody solution was rinsed off with PBS x3 and the secondary antibody goat anti-rabbit 
conjugated to alexafluor-488 (Life technologies A-11008) was added at 1:1000 in blocking 
solution and incubated for 1 hour at ambient temperature.  After a final three rinses with PBS, 
the cells were imaged as described above and composite images were generated by overlaying 
mCherry fluorescence, bright-field, and alexafluor-488 green fluorescence images. 
2.3 RAT HOUSING & INJECTIONS 
Male Sprague-Dawley rats (Charles River, Wilmington, MA) were housed in an animal facility 
with daily monitoring by an onsite veterinarian and staff and twice weekly cage cleaning.  Rats 
had free access to food pellets and water and were housed in pairs when possible for the duration 
of the experiments, consistent with the policies of the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
To ensure safe and accurate injection of HSV-1 vectors and RTX (described below) 
isofluorane anesthesia (Henry Schein Animal Health, Dublin, OH) was used.  Isofluorane was 
selected for its limited duration and rapid recovery time.  For this procedure, rats were placed in 
a sealable container on a porous floor, under which were placed paper towels infused with liquid 
isofluorane.  The container was sealed and rats were monitored and removed at the moment of 
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unconsciousness at which time they were injected, returned to their cage, and monitored until 
fully conscious. 
2.3.1 Vector injection. 
Under isofluorane anesthesia (described above), rats were injected under the skin of the right 
hind footpad with 108 pfu of vector, suspended in 100uL of PBS.  Vector was kept on ice 
between each animal injection and vortexed to maintain homogenization and equal dosing to all 
rats in a group. 
2.3.2 Ivermectin injection. 
Due to its proximity to thermal and mechanical threshold measurements, isofluorane anesthesia 
was not used for ivermectin injections. Instead, rats were allowed to burrow into a folded towel 
for comfort and held in place.  Ivermectin (Sigma I8898) was then injected in 50uL volumes 
under the skin of the hind footpads bilaterally.  Rats were then placed in enclosures for thermal 
or mechanical threshold measurements (described below) and monitored for a 15 minute 
acclimation period at minimum, or until they were calm. 
2.3.3 RTX injection. 
Under isofluorane anesthesia (described above), rats were injected in the left lower quadrant of 
the peritoneum with 200 ug/kg RTX (Sigma R8756) suspended in normal saline with 10% 
Tween 80 & 10% ethanol [138, 149].  After injections, pressure was applied to the injection site 
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and the abdomen was lightly massaged to disperse the RTX solution.  Rats were monitored over 
the next hour for acute side effects and none were observed. 
2.4 TESTS OF NOCICEPTION 
2.4.1 Hargreaves’ test. 
Thermal thresholds were assessed with the Hargreaves’ test.  Rats were placed in a plexiglass 
enclosure on an elevated glass surface, pre-warmed to 30oC.  After a 15 minute acclimation 
period, a high-intensity light beam was focused centrally on the plantar side of the hind paw, 
which starts a timer in the apparatus (Hargreaves apparatus, IITC Life Sciences, Woodland Hills, 
CA).  When a withdrawal response was observed, the beam was switched off and the time 
interval was precisely recorded.  The beam intensity was calibrated such that control responses 
range between 6-8 seconds.  At least four measurements, at greater than five minute intervals 
were made and averaged for the final value.  Fold increase over contralateral (uninjected side) 
was calculated by dividing the ipsilateral average by the contralateral average. 
2.4.2 Von Frey filament test. 
Mechanical thresholds were assessed with the von Frey filament test using the up-down method 
[157, 161].  Rats were placed in a plexiglass enclosure on an elevated wire grid (IITC Life 
Sciences, Woodland Hills, CA).  After a 15 minute acclimation period, von Frey filaments 
(Stoetling, Wood Dale, IL) were applied to the plantar side of the hind paw in increasing 
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thicknesses corresponding to increasing gram-weight force starting from 10g.  Filaments were 
lightly applied, normal to the hind paw and then pushed in until bent.  This force was maintained 
for a total of ~six seconds.  A response was noted if there was a rapid withdrawal, especially 
with subsequent licking of the footpad.  If no response was observed the next thicker filament 
was then applied.  When a withdrawal response was observed, the next thinner filament was then 
applied.  After six observations, the resulting pattern of positive and negative responses were 
interpreted on a table which converts the finding into gram weight threshold by the Weber–
Fechner law.  Fold increase over contralateral (uninjected side) was calculated by dividing the 
ipsilateral average by the contralateral average. 
2.5 STATISTICS 
For the initial thermal threshold modulation experiment, three-way ANOVA was used to 
compare variance in the means of groups using vector type (TRPV1-GlyRIS, NF200-GlyRIS, 
CMV-GlyRIS, or sham), injection side (ipsilateral or contralateral), and ivermectin ligand 
administration (pre-injection measurement or post-injection measurement) as independent 
variables.  The post-hoc Tukey-Kramer test was used for pair-wise comparisons between groups 
whose means were determined to be significantly different by ANOVA.  In Tukey-Kramer tests, 
differences in means were compared to critical values of the Studentized range for multiple 
comparisons with alpha <0.05 (indicated with *) or <0.01 (indicated with **). 
For the RTX experiment, three-way ANOVA was used to compare variance in the means 
of groups using vector type (TRPV1-GlyRIS, NF200-GlyRIS, CMV-GlyRIS, & sham), ivermectin 
ligand administration (pre-injection measurement or post-injection measurement), and RTX 
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status (pre-injection or post-injection) as independent variables.  The post-hoc Tukey-Kramer 
test, which is conservative when comparing groups of unequal sample size (one rat in the CMV-
GlyRIS group died during the course of the experiment) was used for pair-wise comparisons as 
described above. 
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3.0  RESULTS 
3.1 VECTOR DESIGN & CHARACTERIZATION IN DRG CELLS 
In a typical HSV-1 infection when sensory neurons are infected, the virus enters latency and the 
genome becomes heterochromatinized and quiescent, with the possible exception of expression 
from the LAT loci depending on the type of sensory neuron infected [174, 175].  Because the 
goal of this study is transgene expression in sensory neurons, the genome becoming quiescent 
impacts vector design in two ways: extensive crippling mutations to the genome beyond the 
requirement of rendering it replication-defective are unnecessary because the quiescent state will 
limit viral gene expression; also, it is advantageous to utilize the expression-permissive LAT 
locus, flanked by chromatin boundary elements [59, 164, 165], for transgene expression.  
Therefore, the vector was designed with complete deletion of only essential immediate early 
genes ICP4 and ICP27 [58].  The internal repeat region was also deleted resulting in the vector 
genome being stabilized by losing the ability to isomerize [54, 59].  Finally, for ease of insertion 
of a wide variety of transgene constructs, a Gateway destination cassette was inserted into the 
remaining LAT locus, replacing LAT promoter elements.  This cassette contains attachment 
sites, att, evolved in phageλ-E. coli, allowing for highly efficient site-specific recombination 
between the parent vector, vL (Figure 1A) and corresponding att-flanked transgene cassettes on 
plasmids (Figure 1B). 
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In addition to att sites, promoters and the GlyRIS open reading frame, the transgene 
cassettes utilized the complete consensus Kozak translation initiation sequence, the αglobin 
3’UTR for mRNA stability [166, 167], and SV40 polyadenylation sequence (Figure 1B). 
For targeting experiments, the sequence for the neuronal TRPV1 promoter was selected 
based on its previous characterization [168], and the NF200 promoter sequence was obtained 
commercially (sequences in Appendix A). 
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Figure 1. Vector schematic. 
(A) The vector backbone vL was generated from a KOS-based replication-defective vector in which BAC 
sequences were inserted into the TK locus.  Deletions were introduced in the internal repeat region and the 
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genes encoding immediate early proteins ICP4 and ICP27, rendering the vector replication-defective, but 
preserving immediate early genes ICP22 & ICP47.  The Gateway destination cassette was inserted into the 
remaining latency locus, replacing the latency promoter elements while maintaining a wild-type copy of ICP0 
and the surrounding CTCF chromatin boundary elements.  To generate targeted expression vectors, 
transgenes were recombined into the vector backbone via the Gateway cassette. 
(B) Transgene constructs inserted into the HSV vL vector backbone.  pENTR1A, which contains attL sites for 
site-directed recombination with the attR-containing vector backbone was used to generate the transgene 
constructs used.  Between att sites, the highly-stable αGlobin 3’UTR and SV40 polyadenylation signal were 
inserted.  Promoter sequences and transgene ORFs incorporating a Kozak consensus translation initiation 
sequence were inserted into the vector in the combinations shown.  These were then recombined into the vL 
vector backbone to generate the experimental vectors. 
For rat behavior experiments the CMV-GlyRIS control vector utilized was generated from 
the related vH backbone, which was the basis of past rodent pain studies [53, 74, 93] and most 
closely related to the vector used in clinical trials [2, 3]. 
3.1.1 Characterization of vectors in cultured embryonic rat DRG cells. 
To initially characterize whether the promoters were targeting transgene expression to neurons, a 
set of vL vectors were generated to express the red fluorescent marker mCherry.  Several viral 
(Figure 2A top panel) and neuronal promoters (Figure 2A bottom panel) were tested for their 
ability to restrict mCherry expression to neuronal cells within a mixed DRG cell culture of 
neurons and glial support cells.  As controls, the ubiquitously active CMV promoter [171] as 
well as the HSV-1 LAT promoter elements [176, 177] (re-inserted in situ) were used.  These 
were compared to the promoters of neuronal markers TRPV1, expressed in heat-sensitive 
nociceptors; NF200, expressed in proportion to fiber size and therefore highly expressed in large 
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diameter Aβ-fibers; and CGRP, one of the definitional C-fiber peptides classifying the neurons 
expressing it as peptidergic. 
DRG cells were transduced and fluorescence was allowed to develop over 48 hours at 
which point images, displayed as overlays of bright-field and red fluorescence, were taken.  The 
CMV promoter expressed in both neuronal (large round cells) and glial support cells (small 
linear cells).  The LAT promoter as well as all of the neuronal promoters had expression grossly 
limited to neuronal cells.  Of the neuronal promoters tested, the CGRP promoter was striking in 
its intensity and number of cells expressing it.  This is consistent with the fact that the DRG cells 
had been cultured in media containing NGF, which differentiates neurons into the peptidergic C-
fiber lineage.  The LAT promoter expressed at the lowest intensity, which can likely be 
attributed to the fact that downstream enhancer elements, variously referred to as the reactivation 
critical region [178] or LAT promoter 2 (LAP2) [176, 177], contain three translational start sites 
which are upstream of and out of frame with the mCherry start codon.  In Figure 2B, the NF200 
promoter (top panel) and CMV promoter (bottom panel) are compared with the addition of 
antibody staining of endogenous NF200 displayed in green, further illustrating the neuronal-
restricted expression of the NF200-targeted vector compared to the untargeted expression from 
the CMV promoter. 
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Figure 2. Characterization of transgene expression from vectors in cultured DRG cells. 
(A) Expression of mCherry from targeted and control viral vectors in transduced cultured embryonic rat 
DRG cells, demonstrating gross differences in expression pattern and intensity between promoters.  
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Dissociated embryonic DRG cells were cultured for 3 weeks in neurobasal media +NGF and then transduced 
with 3x105pfu of vector (~MOI=3).  At day 2 post transduction, cells were imaged for red fluorescence from 
mCherry. (B) Overlap of vector-derived mCherry expression with the targeted neuronal marker, NF200.  At 
day 2 post transduction, coverslips were fixed and stained with antibodies to NF200.  Red fluorescence from 
vector-expressed mCherry (left column) and NF200 staining in green (center column) was merged to form an 
overlay (right column).  The intensity of red fluorescence from the CMV promoter had to be drastically 
reduced in the overlay for colocalization to be visible (right, bottom). 
3.2 EFFECT OF VECTORS ON NOCICEPTIVE THRESHOLDS IN VIVO 
3.2.1 Targeted silencing of TRPV1+ neurons results in elevated thermal withdrawal 
thresholds. 
To first determine whether a functional outcome of differentially targeted expression of GlyRIS 
could be demonstrated in rats, the heat-sensitive TRPV1 population was selected for modulation 
as assessed by changes in thermal withdrawal thresholds.  The “on-target” TRPV1-targeted (vL) 
vector and “off-target” NF200-targeted (vL) vector were compared to sham-injected rats to test 
the hypothesis that only the TRPV1-GlyRIS transduced rats would demonstrate decreased heat 
sensitivity with increased thermal withdrawal thresholds (Figure 3). 
Vectors or PBS were injected under the skin of the right hind footpad of rats (N=5 per 
group).  After eight days, thermal withdrawal thresholds were measured before and after the 
injection of ivermectin ligand under the skin of the hind footpads.  Injections were done 
bilaterally so that in case the needle injury contributed to hyperalgesia, it would be present on 
both sides. 
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Indeed, only the “on-target” TRPV1-GlyRIS transduced rats showed a significantly 
increased thermal withdrawal threshold after ligand administration.  This threshold was also 
significantly increased from “off-target” NF200-GlyRIS transduced rats and from the rats before 
ligand administration or the contralateral side after administration. 
 
 
Figure 3. Modulating thermal thresholds with targeted GlyRIS expression. 
Paw withdrawal latencies from a radiative heat source (Hargreaves’ test) was measured eight days after 
injection of 108pfu of NF200- or TRPV1-targeted GlyRIS-expressing HSV vector or 100uL PBS sham 
injection under the skin of the right hind footpads of male Sprague-Dawley rats (N=5 for each group).  After 
baseline withdrawal latencies were measured, 50uL of 10uM ivermectin were injected into hind footpads 
bilaterally and after 15 minutes, withdrawal latency measurements were repeated.  For each rat tested, at 
least 4 measurements were taken and averaged. Three-way analysis of variance (ANOVA) using vector, 
injection side, and ivermectin status was used, followed by a post hoc Tukey-Kramer test. Significance 
indicated by *p<0.05, **P<0.01. 
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3.2.2 RTX reveals differential effects of NF200 vs. TRPV1-targeted silencing. 
To determine whether targeted expression of an anti-nociceptive product from HSV-1 vectors 
would demonstrate different functional outcomes based on the neuronal population targeted, 
RTX was employed.  Its reciprocal actions of ablating TRPV1+ heat-sensitive neurons, and later, 
sensitizing large diameter, mechanosensitive neurons by the inflammatory response to 
degenerating neurons [149], provide the opportunity to tease out differential effects of TRPV1 
vs. NF200-targeted vectors in a single experiment (Figure 4).  Repeated from the introduction, 
this experiment tests the hypotheses that: 
1- An anti-nociceptive effect targeted to TRPV1+ neurons will no longer be significantly 
different from other groups when all TRPV1+ neurons are ablated by RTX, and  
2- An anti-nociceptive effect targeted to large, NF200-rich, mechanosensitive fibers will 
reduce the degree of mechanical allodynia caused by RTX-induced inflammation. 
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 Figure 4. Experimental timeline. 
Six rats were assigned to each group based on the vector injected, comparing TRPV1- 
and NF200-targeted GlyRIS vectors (vL) to CMV-GlyRIS vector (vH) and sham-injected control.  
Nine days after vector injection (one day prior to RTX injection), the pre-RTX baseline 
measurement was made.  Thermal and mechanical thresholds were assessed before and after 
ivermectin injection under the skin of the hind footpads bilaterally (the left half of Figures 5 & 6, 
respectively).  This data was represented as fold increase of the transduced side over the 
contralateral side, as done previously on outbred rats [93] to increase the signal from noise 
introduced into von Frey measurements [158] repeated after a long hiatus (21-days while the 
post-RTX mechanical allodynia was being established). 
Replicating the results of the earlier study, thermal thresholds were increased in the 
TRPV1-GlyRIS transduced rats relative to sham and to the rats prior to ligand administration.  
The CMV-GlyRIS transduced rats also had increased thermal thresholds, though to a lesser extent 
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than the TRPV1 vector group.  By pairwise comparisons, the CMV group was significant only 
for increased thermal threshold from prior to ligand administration. 
 
 
Figure 5. Pre-RTX increase in thermal threshold by TRPV1-targeted vector. 
Six rats per group were injected with vectors (108pfu) or vehicle under the skin of the right hind footpads.  
Ten days later, resiniferatoxin (RTX) was injected systemically (200 μg/kg i.p. or vehicle for sham/sham 
group).  Measurements of thermal thresholds using a Hargreaves apparatus were made before and 20 days 
after RTX injection.  For each measurement, thresholds were assessed, ivermectin was injected, and 
measurements were repeated.  Paw withdrawal latencies are the average of at least 4 measurements and 
presented as fold increase over the uninjected side.  Three-way analysis of variance (ANOVA) using vector, 
IVM status, and RTX status was used, followed by a post hoc Tukey-Kramer test. Significance indicated by 
*p<0.05, **P<0.01. 
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RTX was delivered systemically by i.p. injection and rats were allowed to rest for 20 
days for mechanical allodynia to develop.  After that period, the post-RTX measurement was 
made (Figures 5 and 6, right half). 
Post-RTX ablation of TRPV1+ neurons, the thermal thresholds had equalized between 
the transduced side & contralateral and between groups as expected (Figure 5). 
When mechanical thresholds were assessed, the NF200-GlyRIS transduced group alone 
demonstrated reduced mechanical allodynia on the transduced side relative to the contralateral 
side after ligand administration, resulting in an ipsilateral/contralateral ratio which was 
significantly greater than all other groups, in accordance with the hypothesis (Figure 6). 
 
 
Figure 6. Post-RTX reduction in mechanical allodynia by NF200-targeted vector. 
Six rats per group were injected with vectors (108pfu) or vehicle under the skin of the right hind footpads.  
Ten days later, resiniferatoxin (RTX) was injected systemically (200 μg/kg i.p. or vehicle for sham/sham 
group).  Measurements of mechanical thresholds using von Frey filaments and quantified by the up-down 
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method were made before and 20 days after RTX injection.  For each measurement, thresholds were assessed, 
ivermectin was injected, and measurements were repeated.  Paw withdrawal thresholds are presented as fold 
increase over the uninjected side.  Three-way analysis of variance (ANOVA) using vector, IVM status, and 
RTX status was used, followed by a post hoc Tukey-Kramer test. Significance indicated by *p<0.05, 
**P<0.01. 
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4.0  DISCUSSION 
The field of gene therapy has grown exponentially over the past decade, gaining back the 
momentum that was lost with the missteps of the 1990s and early 2000s, including insertional 
mutagenesis from early retroviral vectors resulting in post-therapy leukemia [179], and poorly 
conducted trials culminating in the 1999 death of trial subject Jesse Gelsinger [180].  Since then, 
large strides have been made to improve vector safety.  Focus has shifted away from earlier 
promiscuously integrating retroviral vectors toward viral vectors with minimal or no risk of 
insertional mutagenesis and low immunogenicity. 
The safety and efficacy of gene therapy has seen the greatest improvement with the 
advancement of gene targeting technology on the transductional [119, 125], transcriptional [124-
126], and post-transcriptional level [127].  
By using several of these techniques in concert, the contemporary gene therapy 
investigator has a well-stocked vector targeting toolbox to employ to maximize the likelihood of 
successful transduction of the target cell type while minimizing unwanted side-effects. 
This study was able to demonstrate a functional consequence of promoter-targeting 
GlyRIS expression.  Specifically, TRPV1-targeted vectors were able to elevate baseline thermal 
thresholds (Figure 3), an effect that was no longer different from controls after RTX-ablation of 
TRPV1+ neurons (Figure 5); and NF200-targeted vectors were able to reduce mechanical 
allodynia following RTX insult (Figure 6).  While the RTX model is not directly clinically 
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relevant, it does serve as proof of principle that using neuronal promoters to target the expression 
of an anti-nociceptive product from HSV-1 vectors to distinct neuronal populations is a viable 
strategy to achieve differential effects on nociception. 
It is noteworthy that the TRPV1-targeted vectors outperformed the CMV vector in pre-
RTX thermal threshold elevation and furthermore, the CMV vector had no effect in post-RTX 
mechanical allodynia reduction (only the NF200-targeted vector had this effect).  This could be 
attributed to some combination of the following factors.  Firstly, the vH-derived CMV vector 
used, though KOS-based and similar in the genes deleted to render it replication-defective [58, 
163], was not an identical backbone to the vL-derived neuronal promoter-targeted vectors.  The 
vH backbone was used as a standard of comparison, as it was the basis for several previous 
therapeutic vectors engineered by the Glorioso lab, used in previous pain studies [53, 74, 93], 
and very similar to the vector used in clinical trials [2, 3].  The principal difference between 
vector backbones was the transgene insertion site.  Whereas the promoter-targeted vectors 
utilized the vector’s remaining LAT locus to take advantage of its flanking chromatin boundary 
elements [59, 165], allowing permissive transcription from this site in sensory neurons in which 
its native product LAT is expressed, the vH-based vector has the CMV-GlyRIS transgene inserted 
into both ICP4 loci.  Therefore, one possible explanation for this vector’s lack of effect in 
reducing post-RTX inflammatory mechanical allodynia may be the heterochromatinization of 
these loci over the 30 days from vector injection to this measurement.  By extension, these loci 
may have been earlier in their trajectory towards quiescence at the pre-RTX measurement nine 
days after vector injection, which may account for its lower degree of thermal threshold 
elevation relative to the TRPV1-targeted vector at the time of that measurement. 
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A related consideration is that the CMV promoter [171] itself is known to be rendered 
quiescent over time in vivo, presumably due to cis elements directing its heterochromatinization.  
If this was the dominant factor in its quiescence, one would expect the CMV promoter to be 
similarly repressed in other loci and a poor choice for long term expression in animals and 
patients.  This is consistent with the effect of preproenkephalin expression being diminished, but 
not eliminated over the 7 weeks of initial experiments [64] and over the 28 days of the clinical 
trial [3]. 
An alternate, though less probable explanation for the neuronal promoters outperforming 
the CMV promoter would be some degree of cell-type specific expression from the CMV 
promoter.  The CMV promoter, while conventionally regarded as capable of expressing gene 
products to high levels in any cell type, could potentially exhibit its own degree of specificity for 
expression in a subset of neurons.  Even if this subset is large, if it excludes critical TRPV1+ or 
NF200+ neurons necessary for the effects observed with targeted promoters in pre- and post-
RTX observations, this could in part account for its diminished or absence effect in this study.  
This could be evaluated in further targeting studies comparing several different ubiquitously 
expressing promoters in different loci. 
4.1 FUTURE DIRECTIONS 
4.1.1 Assessment of targeting efficiency comparing promoters and promoter size. 
To lend further support for the targeting method employed in this study, the immediate next step 
will be to directly assess targeting efficiency.  Specifically, I would propose an experiment in 
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which a short and long size of each promoter is selected to drive the expression of a fluorescent 
marker (e.g. mCherry).  These vectors can be easily generated using the Gateway site-directed 
recombination system incorporated into the vL parent vector, recombined with the desired 
plasmid transgene constructs.  Once these vectors are generated, hind paw injections can be 
carried out using the same methodology as in this study.  After a 7-30 day interval, DRG would 
be harvested for tissue sections and immuno-staining for the two targeted neuronal markers 
(TRPV1 or NF200).  Targeting efficiency would be determined as the proportion of total vector-
driven fluorescent cells which co-stain for the marker of interest.  The expectation would be that 
for each marker, the CMV promoter would have a low targeting efficiency – expressing non-
specifically in most or all transduced neurons.  Also, the vector miss-matched for targeting to the 
immuno-stained population (i.e. sections from rats injected with TRPV1-targeted vector, then 
assessed for NF200 targeting, or vice versa) would have low targeting efficiency to that cell type, 
reflecting low overlap of those two markers.  Only the vector targeted to the stained marker 
would be expected to have high targeting efficiency.  Finally, it could be determined whether 
incorporating a larger putative promoter sequence would result in higher targeting efficiency.  
One of the strengths of the HSV vector platform is a large carrying capacity.  Therefore, it would 
be possible to use up to tens of kilobase-pairs of putative promoter sequence if the greater length 
was determined to correlate to a higher targeting efficiency. 
4.1.2 Generating a suite of promoter-targeted HSV vectors to test hypotheses about 
nociceptor subpopulation involvement in specific pain models. 
Using the vL parent vector designed for this study, there is the potential to easily generate a large 
suite of differentially-targeted vectors by inserting different neuronal promoters driving GlyRIS, 
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into the vector backbone.  Single vectors could be generated to test specific hypotheses or a 
collection of differentially-targeted anti-nociceptive vectors could be collectively tested on 
specific pain models.  It would be expected that the degree to which a given vector alleviated 
pain would be in direct proportion to the involvement of the targeted neuronal population in that 
pain type. 
A high yield direction to explore would be to select nociceptor marker genes which could 
dissect this diverse category of neurons based on different functional products.  One principal 
way in which nociceptors are classified is based on the expression of neuropeptides – substance 
P (SP) and calcitonin gene related peptide (CGRP) – which define their neurons as peptidergic.  
Peptidergic nociceptors develop from neuronal precursors stimulated by NGF in embryonic 
development, whereas non-peptidergic nociceptors switch from NGF to GDNF [21].  Peptidergic 
nociceptors synapse in lamina I and the outer portion of lamina II of the dorsal horn of the spinal 
cord, while non-peptidergic neurons synapse in inner lamina II.  There are functional 
consequences to these differences in expression and connectivity [181].  Peptidergic nociceptors 
have been implicated in inflammatory pain and non-peptidergic nociceptors have been 
implicated in neuropathic pain [12, 23].  By using the promoters of SP and CGRP, it would be 
possible to determine the contribution of these two types of peptidergic nociceptors to 
inflammatory pain models and others.  In contrast, non-peptidergic nociceptors express fluoride 
resistant acid phosphatase (FRAP) [182], neuropeptide responsive GPCRs MrgA & MrgD, and 
the purinergic receptor P2X3 [183].  By using their promoters, the contribution of subpopulations 
of non-peptidergic nociceptors to neuropathic pain models and others could be determined. 
Another way to distinguish populations of nociceptors is by the expression of distinct ion 
channel sensors, rendering the neuron sensitive to distinct stimuli.  The example from this study 
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is TRPV1, a channel sensitive to heat, protons, and several biological compounds such as 
capsaicin and RTX.  There are many TRP channels which mediate the detection of various 
thermal, mechanical, and chemical stimuli [184, 185].  In addition to TRPV1, a couple good 
candidate genes of this type to use for promoter-targeting would be TRPA1, which is activated 
by cold and many chemical irritants including formalin [186], and TRPM8 which is activated by 
a wide array of cold stimuli and menthol [187]. 
In addition to neuropeptide classification and the presence of specific receptors, there are 
other markers which correlate to physical differences between neurons.  The neurofilaments fall 
into this category.  NF200 which was targeted in this study is the heavy neurofilament (also 
called NFH).  The other peripheral neurofilaments are neurofilaments light & medium (NFL & 
NFM) and peripherin [188].  The expression of NF200 scales with neuron size and as such it was 
selected to target large-diameter fibers which tend to be mechanosensitive, non-nociceptive 
neurons, but which can be recruited to pain signaling following trauma or chemical irritation.  
Other neurofilament promoters could be used to preferentially express in neurons based on the 
relative abundance of these structural molecules, allowing for the dissection of primary afferents 
along a cytostructural axis.   
Finally, there are genes products which are induced in certain pain states.  TRPV1 for 
instance has been shown to be differentially upregulated in certain neuronal populations 
following inflammation [189] or nerve injury [190].  It will be important to determine whether 
exogenous promoters on viral vectors will follow a similar induction pattern.  The identification 
of pain-inducible promoters and promoter elements may aid in expression when correctly 
matched to the pain model or syndrome causing its induction.  Another promising lead in this 
direction would be the use of the neuropeptide Y (NPY) promoter.  NPY has limited expression 
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in the PNS under normal conditions, but is highly upregulated following nerve injury [191, 192].  
Using this promoter has the potential of adding an additional level of targeting – phenotypic 
targeting – as it may be nearly quiescent in normal conditions, but provide for the inducible 
expression of GlyRIS in the pain state. 
4.1.3 Advancement to clinical trials. 
The ultimate purpose of developing targeted anti-nociceptive vectors is to treat patients with 
chronic pain.  As such, the future direction of greatest importance is to identify one or more 
vectors with the highest likelihood of treating a known pain syndrome.  The next step in 
identifying such a vector is the testing of vectors on carefully chosen, clinically relevant pain 
models.  One in particular is very appealing: post-herpetic neuralgia (PHN). 
PHN is persistent pain after the resolution of an episode of herpes zoster (shingles).  
Zoster itself represents a reactivation event of latently infected varicella zoster virus (VZV) from 
its reservoir within sensory ganglia, a tropism it shares with the closely related HSV.  This 
causes replication within the ganglion and subsequent anterograde transport of virions to the 
corresponding dermatome, where further virus replication can result in a visible lesion.  Both 
zoster and PHN can result in intense allodynia and are the cause of significant reductions in 
quality of life [193]. 
As a consequence of replication within sensory ganglia, pain caused by zoster and PHN 
is localized and originates from a PNS lesion.  This makes PHN an attractive target for 
interventions at the level of the PNS, like anti-nociceptive gene therapy.  PHN is an attractive 
target for HSV anti-nociceptive gene therapy for additional reasons.  Firstly, based on the shared 
tropism of VZV and HSV, both alphaherpesviruses, the insult resulting in chronic neuropathic 
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pain is in the precise tissue which HSV has evolved to transduce: sensory neurons.  In other 
words, HSV is the ideal delivery vehicle to treat the pain syndrome caused by its sister virus 
VZV.  Secondly, PHN can be recapitulated in a rat model by infecting rats with VZV-infected 
cells in the same manner as the vector injections in this study [93].  This would mean that using a 
protocol similar to that used in this study, one or several targeted HSV vectors could be 
evaluated in a very clinically relevant model – using the causative agent for human disease, not a 
contrived chemical irritant or surgical injury. 
To have the greatest chance to identify an effective targeted vector to reduce PHN pain in 
a rodent model, a suite of promoter-targeted vectors like the one described in the above section 
should be tested and compared to constitutively active promoters like CMV or the ubiquitin 
promoter for the ability to reduce pain behaviors in evoked and spontaneous pain tests using the 
PHN model.  The most effective of these vectors would be a prime candidate for advancement to 
clinical trials for the treatment of PHN. 
The use of an ivermectin-sensitive mutant glycine receptor instead of the wild-type GlyR 
was intended to facilitate translation of this technology to the clinic.  Oral and topical 
preparations of ivermectin are FDA approved for the treatment of certain helminthic infections 
[113], which is a strong testament to the safety of this drug.  Additional pre-clinical studies will 
need to be conducted to determine the dose of topical or oral ivermectin necessary to activate 
vector-delivered GlyRIS channels.  The ultimate intent of targeted vectors delivering this channel 
will be that their activation will be conditional on the use of an ivermectin topical cream, 
extended release patch, or pill.  In this way, pain relief from therapeutic HSV-1 vectors will be 
able to be controlled and modulated by a treating physician to serve the needs of an individual 
patient. 
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4.2 CONCLUDING REMARKS 
The flexibility of using neuronal promoters in HSV-1 vectors to achieve targeted silencing of a 
given population of sensory neurons, defined by the expression of a marker gene, presents the 
enticing possibility of using a suite of targeted vectors to test hypotheses about which population 
of sensory neurons mediates a specific pain type.  These genetic tools have the potential to 
increase the resolution of our understanding of the nociceptor subpopulations responsible for the 
maintenance of chronic pain and may ultimately result in highly targeted pain therapy.  
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APPENDIX A 
TRANSGENE SEQUENCES 
A.1 CMV PROMOTER 
ATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTAC
ATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGAC
GTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGC
CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC
GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTT
GACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGG
CACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCA
AATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGC 
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A.2 NF200 PROMOTER 
GTAGGTTCTCTGCCCCTCAAACTCAGCCCAGCTTTCTCCTGCCTGTTCAGGGGACCTT
CTGCCCGCTTCGCTGAGGGTCCGTCCCCTTTACTGGGGCTGGCAGCAGGGTCTCCCA
TCTCCTCTCTCGGGGGCCACTGCAGACTTTTTAGAGAACGCCTTGCCTCCCCCCAAC
CCCACCCATCCGGGGTTCCCTCTCTCCATCCTCTGCAGTGTCTCCCATACCCCCATTC
AGGGTAGCCTTGCTATTCTCCCCAACTCCAGGTCCCCCTTCATCTATTCCGGGGCTGG
CCGCGGAGTTTCCTGAGCGCTCTCCAAGTGGGTCCTCTAGATGTTAGGAGAACACTG
TACCTCCCCCGGTCAGGGGTCTCCTGTCTCCGTTCTATGGAGCGTCCATGCTCCCATT
CAGGACTGCCTTGCTCCCTCCTCTGTTCCGGGGCTGGCTGCACAGTCTCTGCACCCCC
TATCCTGAAAGCCTCTCTTAACTATTTGGAAAGCCTCGTGTCCTGTCTCATACAGGG
ATCCCCTCATCCTAATGACTGCAATCTTCCATTGCTCCATCCCGAGGGCATCCTGCCC
CTATTCCCATCAGGTTTCTCCTTGTCCTCTCCCTGTTTCAAGTCCCCTTTCTTATTCCG
AACACACTCGCAGGCTCTTCCGACGCGCACCCGGGGGTCCTCACTGGCCCACTCCGG
GAGTCCTCTGCCCGCTTCCCCGACCTCGAGGGTCTCCTCTGACGCAGCGTCGATTCC
CCTTCCCTCCTCGGTCCCCTGCCCCGCCCCTCTCACTGCGGCGGAGCCGGTCGGCCG
GGGGGCCGCAGGGGAGGAGGCGGAGAGGGCGGGGCCCTCCTCCCCACCCTCTCACT
GCCAAGGGGTTGGACCCGGCCGCGGCGGCTATAAAAGGGCCGGCGCCCTGGTGCTG
CCGCAGTGCCTCCCGCCCCGTCCCGGCCTCGCGCACCTGCTCAGGCCATGAT 
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A.3 TRPV1 PROMOTER 
CAGCTTTTGTACTTCTCCAGGCGGAGCTGCCGTGGCTGCTCCACTGGAGCAGTGTCT
GAAAAAAAAATAAAAAGGAAAGAAAAGGACATGACTGTTTTTCGGTGCGGTGGAA
GAGAAAGTTTATTGTAGATAAAGGGGGAGCATAGACAGAGGCAGACATGTCTGGGA
GAGCCAGAGTGGTTGTGACCCTGAGCCATATGGAGAGGTGGGGTGAGGGGTGGCAG
AGAGGGATCGAGAGAGGAGAGAGGGGAACCAGATGTAGCAGCCAGGAGGCCAAAG
GTACAAAAGGGGTGGGTAACCAAAATGTCTGGATTATATAAAAAAGAGCCAGAGGT
CAGGCCCACTTTGATATGTTAAATAGGCACCTCAGCCATTTATCCAGGTTTGAAATG
TAATATAATTTACATCCCCCTGGCTTCCTAGAGACCGTTGTTTAGACGGATGACCTCT
GCAGAATGTTTGAGGGTGCAGTCTTGCATGTACTCCCTGGTGGGCTTTCTTGGGCAG
GATCTGGGCAGGAATGGGCTTGTTCTAGTCACCCACTGCGTATGATGGATGAACCCG
CTTCCTAGTAGTTAGGATGGCACTGGGGGAGGCGAGAAATTAGCACACGTAACGTT
TTCTTGTGTTCTATTGTTCACTAAGGGACCCCAGTCAAGCAAGACTGGGCCTTGGAA
GACCTAGAGACCACCAAACCTAATCTCTACCCCGGGTCTGAGTACACAGGGACTCA
GAGTCCCAAAGGGGGCAGGGCCTCCAGACAGGTGGCTCAGAGGTCCCAGTCCTTTG
GAAACATGGCATCTTCAGGACACTGGGCTTTGCATCTCTGGCTGTGACAGTCCTTTA
AGGGAGCTACTCCTCAGACATACAGGAGAGATGGTTTGGAAAGTCCGAGATCCAAA
GCCTGGTTCAGGCTGGACTGGGCTGCAGGCTGCTAAGTGCTCCTCTGCCCTGGCATG
GCTGGGGGTGGGGCATTGGCTGTGGTTCCTGAAAAAGGGCAAAAATGATGGGAAAA
GCTTTGGGATCCTCTGGGAATCGGAGCCGTGGTAACAGCAGCTGCTGCCATTGCTGC
AAATGTTTCCTTGAGTGCCAGAGTATGCCCAGAGCCCATCCCTGCCGTACGCCAGGG
GAGGGGCGAGGACCCTCACAGAGGCAGGGAGGCCGGCCACTCTTACCACACAGCA
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GCCTGGCTCTCCCACAAAGGACAGCTCCAAGGCACTTGCTCATTTGGGGTGTAAGGG
CGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGATC 
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A.4 GLYRIS 
GCCGCCACCATGTACAGCTTCAATACTCTTCGACTCTACCTTTGGGAGACCATTGTAT
TCTTCAGCCTTGCTGCTTCTAAGGAGGCTGAAGCTGCTCGCTCCGCACCCAAGCCTA
TGTCACCCTCGGATTTCCTGGATAAGCTAATGGGGAGAACCTCCGGATATGATGCCA
GGATCAGGCCCAATTTTAAAGGTCCCCCAGTGAACGTGAGCTGCAACATTTTCATCA
ACAGCTTTGGTTCCATTGCTGAGACAACCATGGACTATAGGGTCAACATCTTCCTGC
GGCAGCAATGGAACGACCCCCGCCTGGCCTATAATGAATACCCTGACGACTCTCTG
GACCTGGACCCATCCATGCTGGACTCCATCTGGAAACCTGACCTGTTCTTTGCCAAC
GAGAAGGGGGCCCACTTCCATGAGATCACCACAGACAACAAATTGCTAAGGATCTC
CCGGAATGGGAATGTCCTCTACAGCATCAGAATCACCCTGACACTGGCCTGCCCCAT
GGACTTGAAGAATTTCCCCATGGATGTCCAGACATGTATCATGCAACTGGAAAGCTT
TGGATATACGATGAATGACCTCATCTTTGAGTGGCAGGAACAGGGAGCCGTGCAGG
TAGCAGATGGACTAACTCTGCCCCAGTTTATCTTGAAGGAAGAGAAGGACTTGAGA
TACTGCACCAAGCACTACAACACAGGTAAAGCCACCTGCATTGAGGCCCGGTTCCA
CCTGGAGCGGCAGATGGGTTACTACCTGATTCAGATGTATATTCCCAGCCTGCTCAT
TGTCATCCTCTCATGGATCTCCTTCTGGATCAACATGGATGCTGCACCTGCTCGTGTG
GGCCTAGGCATCACCACTGTGCTCACCATGACCACCCAGAGCTCCGGCTCTCGAGCA
TCTCTGCCCAAGGTGTCCTATGTGAAAGCCATTGACATTTGGATGGGAGTTTGCCTG
CTCTTTGTGTTCTCAGCCCTATTAGAATATGCTGCCGTTAACTTTGTGTCTCGGCAAC
ATAAGGAGCTGCTCCGATTCAGGAGGAAGCGGAGACATCACAAGGAGGATGAAGCT
GGAGAAGGCCGCTTTAACTTCTCTGCCTATGGGATGGGCCCAGCCTGTCTACAGGCC
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AAGGATGGCATCTCAGTCAAGGGCGCCAACAACAGTAACACCACCAACCCCCCTCC
TGCACCATCTAAGTCCCCAGAGGAGATGCGAAAACTCTTCATCCAGAGGGCCAAGA
AGATCGACAAAATATCCCGCATTGGCTTCCCCATGGCCTTCCTCATTTTCAACATGTT
CTACTGGATCATCTACAAGATTGTCCGTAGAGAGGACGTCCACAACCAGTGA 
 
Mutations from wild-type GlyR (bold & underlined) 
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A.5 PEPAGPA MULTIPLE CLONING SITE 
CTTAAGCTCGGGCCCCAAATAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGC
AACAAATTGATAAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGCAGGCT
TTGGGTTTAAACCCAAAGGAACCAATTCAGTCGACTGGATCCGCTGGAGCCTCGGT
AGCCGTTCCTCCTGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGGC
CCTTCCTGGTCTTTGAATAAAGTCTGAGTGGGCAGCGCGGCCGCACTCGAGATCCAACT
TGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAA
ATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
TTATCATGTCATCTAGACCCAGCTTTCTTGTACAAAGTTGGCATTATAAGAAAGCAT
TGCTTATCAATTTGTTGCAACGAACAGGTCACTATCAGTCAAAATAAAATCATTATT
TGCCATCCAGCTGCAGCTC 
 
PmeI promoter insertion site (bold & underlined) 
HincII ORF insertion site (bold & underlined) 
αGlobin 3’UTR (italicized & underlined) 
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